In this study, we found that adjunct pulse methylprednisolone therapy could significantly improve the mortality rate, duration of hospitalization, recovery rate, SpO2, oxygen requirement, and laboratory parameters (CRP, D-dimer, IL-6, ferritin, and LDH levels) compared to standard treatment alone in patients with severe COVID-19 at risk of hyperinflammatory response. This evidence concerns the gene IL6 and COVID-19.